Company: BSX
Filing Date: 2025-11-03
Form Type: 10-Q
Source: 0000885725-25-000050
Chunk: 151

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-11-03
Form: 10-Q
Item: Part I, Item 8
Chunk 151
---
able segments and to allocate resources across our reportable segments. Refer to Note K – Revenue for net sales by reportable segment presented in accordance with GAAP.A reconciliation of sales and operating income for the reportable segments to the applicable line items within our accompanying unaudited consolidated statements of operations is as follows (in millions, except percentages). Prior period amounts have been restated at constant currency to conform to current year presentation. 

31

Table of Contents

Three Months Ended September 30, 2025MedSurg% of net salesCardiovascular% of net salesTotalNet sales of reportable segments$1,714 $3,327 $5,041 Impact of foreign currency fluctuations23 Total net sales5,065 Segment expenses:Cost of products sold483 28.2 %930 27.9 %1,413 Selling, general and administrative expenses531 31.0 %920 27.6 %1,451 Research and development expenses128 7.5 %337 10.1 %465 Other segment items(1)5 0.3 %6 0.2 %11 Segment operating income(2)566 33.0 %1,135 34.1 %1,701 Unallocated amounts:Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments(282)Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs(146)Amortization expense(225)Operating income (loss) 1,048 Other income (expense), net(110)Income (loss) before income taxes$939 

32

Table of Contents

Nine Months Ended September 30, 2025MedSurg% of net salesCardiovascular% of net salesTotalNet sales of reportable segments$5,027 $9,801 $14,827 Impact of foreign currency fluctuations(39)Total net sales14,788 Segment expenses:Cost of products sold1,388 27.6 %2,901 29.6 %4,289 Selling, general and administrative expenses1,557 31.0 %2,695 27.5 %4,252 Research and development expenses369 7